Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in fundsnews2025-05-20T04:01:33+00:00May 20th, 2025|Endpoints News|
Prime Medicine sidelines only clinical program, replaces CEO and lays off some staffnews2025-05-19T15:33:27+00:00May 19th, 2025|Endpoints News|
Intellia’s CRISPR therapy likely causes ‘permanent’ gene knockdown in ATTR amyloidosisnews2025-05-19T15:14:34+00:00May 19th, 2025|Endpoints News|
David Liu, Sam Sternberg unveil new way to insert big genes in human cellsnews2025-05-19T14:31:07+00:00May 19th, 2025|Endpoints News|
#ASGCT25: Lower conference attendance mirrors challenged cell and gene fieldnews2025-05-16T16:33:44+00:00May 16th, 2025|Endpoints News|
#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promisenews2025-05-16T15:25:53+00:00May 16th, 2025|Endpoints News|
Eli Lilly teams up with RNA editing biotech for hearing lossnews2025-05-15T17:30:49+00:00May 15th, 2025|Endpoints News|
Philadelphia doctors treat infant with first custom CRISPR therapy that fixes genetic mutationnews2025-05-15T17:00:12+00:00May 15th, 2025|Endpoints News|
Advocacy groups and experts call for decade-long ban on germline editingnews2025-05-14T10:00:09+00:00May 14th, 2025|Endpoints News|
CRISPR patent spat revived by federal appeals court rulingnews2025-05-13T20:05:09+00:00May 13th, 2025|Endpoints News|
